Brokerages Anticipate Minerva Neurosciences Inc (NASDAQ:NERV) to Announce -$0.41 EPS

Analysts predict that Minerva Neurosciences Inc (NASDAQ:NERV) will post earnings of ($0.41) per share for the current quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Minerva Neurosciences’ earnings. The highest EPS estimate is ($0.36) and the lowest is ($0.49). Minerva Neurosciences posted earnings per share of ($0.34) during the same quarter last year, which would indicate a negative year over year growth rate of 20.6%. The company is expected to announce its next earnings results on Tuesday, March 10th.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

On average, analysts expect that Minerva Neurosciences will report full year earnings of ($1.48) per share for the current fiscal year, with EPS estimates ranging from ($1.58) to ($1.44). For the next financial year, analysts anticipate that the firm will post earnings of ($1.69) per share, with EPS estimates ranging from ($3.32) to ($0.91). Zacks’ EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Minerva Neurosciences.

Minerva Neurosciences (NASDAQ:NERV) last released its quarterly earnings results on Monday, November 4th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.37) by $0.01.

A number of equities research analysts recently weighed in on the company. William Blair assumed coverage on Minerva Neurosciences in a report on Wednesday, September 18th. They set an “outperform” rating and a $26.00 price target for the company. Chardan Capital reaffirmed a “buy” rating and set a $17.00 price target on shares of Minerva Neurosciences in a report on Tuesday, October 1st. ValuEngine cut Minerva Neurosciences from a “strong-buy” rating to a “buy” rating in a report on Monday, September 30th. Zacks Investment Research cut Minerva Neurosciences from a “buy” rating to a “hold” rating in a research note on Tuesday, October 29th. Finally, BidaskClub raised Minerva Neurosciences from a “strong sell” rating to a “sell” rating in a research note on Friday, August 23rd. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $17.44.

NERV stock traded up $0.27 during midday trading on Friday, reaching $5.97. 418,132 shares of the company’s stock traded hands, compared to its average volume of 380,841. The company has a 50-day simple moving average of $4.69 and a two-hundred day simple moving average of $6.02. Minerva Neurosciences has a 1-year low of $4.01 and a 1-year high of $9.12. The company has a market cap of $216.98 million, a price-to-earnings ratio of -4.65 and a beta of 1.50.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Jacobs Levy Equity Management Inc. increased its stake in shares of Minerva Neurosciences by 39.2% in the 2nd quarter. Jacobs Levy Equity Management Inc. now owns 184,311 shares of the biopharmaceutical company’s stock valued at $1,038,000 after buying an additional 51,942 shares during the period. TD Asset Management Inc. increased its stake in shares of Minerva Neurosciences by 2.8% in the 2nd quarter. TD Asset Management Inc. now owns 58,847 shares of the biopharmaceutical company’s stock valued at $331,000 after buying an additional 1,600 shares during the period. Russell Investments Group Ltd. increased its stake in shares of Minerva Neurosciences by 270.3% in the 2nd quarter. Russell Investments Group Ltd. now owns 21,224 shares of the biopharmaceutical company’s stock valued at $119,000 after buying an additional 15,492 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in shares of Minerva Neurosciences in the 3rd quarter valued at $35,000. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of Minerva Neurosciences in the 2nd quarter valued at $464,000. 73.96% of the stock is owned by institutional investors.

About Minerva Neurosciences

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. The company's lead product candidate is roluperidone, which is in Phase III clinical trial, a compound for the treatment of patients with schizophrenia.

Featured Article: What strategies should day traders use to execute a trade?

Get a free copy of the Zacks research report on Minerva Neurosciences (NERV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Minerva Neurosciences (NASDAQ:NERV)

Leave a Reply

Your email address will not be published. Required fields are marked *

*